U.S. Oral Solid Dosage Contract Manufacturing Market Size, Share & Trends Analysis Report By Product Type (Tablets, Capsules), By Mechanism (Controlled-, Immediate-release), By End-user, And Segment- Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2023-2032

The U.S. oral solid dosage contract manufacturing market size was estimated at USD 10.85 billion in 2022 and is expected to hit around USD 19.8 billion by 2032, poised to reach at a notable CAGR of 6.2% during the forecast period 2023 to 2032.

U.S. Oral Solid Dosage Contract Manufacturing Market Size, 2023 to 2032

Key Takeaways:

  • Based on product type, the tablets segment accounted for the largest market share of 32.23% in 2022.
  • The capsules segment is anticipated to register lucrative growth during the forecast period.
  • The controlled release segment dominated the market and accounted for the largest revenue share of 51.91% in 2022.
  • The immediate release segment is expected to advance at a substantial CAGR during the forecast period.
  • The large-size companies segment dominated the U.S. oral solid dosage contract manufacturing market with the highest revenue share of 54.97% in 2022.
  • The medium and small size companies segment is expected to progress at a substantial CAGR during the forecast period.

U.S. Oral Solid Dosage Contract Manufacturing Market Report Scope

Report Attribute Details
Market Size in 2023 USD 11.52 Billion
Market Size by 2032 USD 19.8 Billion
Growth Rate From 2023 to 2032 CAGR of 6.2%
Base Year 2022
Forecast Period 2023 to 2032
Segments Covered Product type, Mechanism, End-user 
Market Analysis (Terms Used) Value (US$ Million/Billion) or (Volume/Units)
Report Coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Key Companies Profiled Catalent, Inc.; Lonza; AbbVie Inc.; Aenova Group; Adare Pharma Solutions; Boehringer Ingelheim International GmbH; Jubilant Pharmova Limited; Patheon Pharma Services; Recipharm AB; Corden Pharma International; Siegfried Holding AG

 

Advancements in drug delivery technology and increasing investments by Contract Development and Manufacturing Organizations (CDMOs) to enhance Oral Solid Dosage (OSD) development are major factors driving market growth. Technological advancements pertaining to the development and bulk manufacturing of OSD forms are the primary factors fast-tracking the commercialization of these products. Currently, a diverse array of dosage forms is accessible in the market. Nutraceutical and pharmaceutical industries consistently strive to develop OSD forms due to their ease of handling and consumption, and favorable adherence among patients.

Oral Solid Dosage (OSD) medications have exhibited substantial potential in alleviating COVID-19 symptoms. Pharmaceutical companies expedited the research, development, and distribution of pharmaceuticals to overcome the disease and address its signs. While significant attention globally was directed toward vaccine prospects, an alternative avenue displayed encouraging results, such as small-molecule OSD treatments such as hydroxychloroquine and azithromycin. Originally designed for less prevalent conditions such as malaria, these OSD medications gained immense traction as their efficacy against COVID-19 symptoms gained recognition.

Moreover, increasing demand for outsourcing OSD manufacturing among pharmaceutical companies has compelled contract manufacturers to expand their manufacturing facilities to support this growing demand. These expansions are made across the globe to increase their penetration in the OSD industry. Furthermore, the rising demand for generic drugs is also a key factor, given that many generics are OSD products. For instance, in April 2020, CoreRx, Inc., a CDMO, opened a new product development center in Clearwater, Florida to manufacture oral and topical dosage formulations.

Product Type Insights

Based on product type, the tablets segment accounted for the largest market share of 32.23% in 2022. Solid dosage products, particularly tablets, are considered economical, which is anticipated to promote segment growth. Furthermore, the tablet segment continues to embrace new technologies, such as continuous manufacturing and 3D printing, for further improvement in the efficiency of manufacturing processes, aiding segment growth. For instance, in May 2023, an Ohio-based contract manufacturer, The Technology House (TTH), acquired an SLA 750 3D printer from 3D Systems to improve and streamline its manufacturing processes.

The capsules segment is anticipated to register lucrative growth during the forecast period. The adoption of capsules in Oral Solid Dosage (OSD) forms due to various advantages, such as ease of swallowing, faster disintegration, and convenient absorption, is expected to drive market growth. Capsules can disintegrate more quickly, resulting in a more rapid medication release and absorption. This is advantageous for medicines that need to start working quickly.

Mechanism Insights

The controlled release segment dominated the market and accounted for the largest revenue share of 51.91% in 2022. Recent advancements within the domain of oral controlled-release delivery systems, including dome tablets, dual drug tablets, intestinal patches, polymer nanosystems, and bioinspired delivery methods like exosomes have revolutionized the field, as Controlled-Release (CR) drug delivery systems maintain their pivotal role in disease treatment.

The immediate release segment is expected to advance at a substantial CAGR during the forecast period. The adoption of IR oral solid dosage forms has increased due to various factors that make them favorable for pharmaceutical developers and patients. IR formulations are made to rapidly release the active pharmaceutical ingredients (APIs) after consumption, immediately initiating the therapeutic effects. This is especially advantageous for drugs that need to provide instant relief or rapid symptom relief. Thus, the increasing adoption of IR dosage forms is expected to drive segment growth.

End-user Insights

The large-size companies segment dominated the U.S. oral solid dosage contract manufacturing market with the highest revenue share of 54.97% in 2022. Large companies mostly prefer to avoid getting engaged in manufacturing difficulties and instead concentrate on their core skills, such as research, development, marketing, and distribution. Contract manufacturing allows them to concentrate on what they do best while leaving the manufacturing aspect to experts.

On the other hand, the medium and small size companies segment is expected to progress at a substantial CAGR during the forecast period. Research and development are frequently prioritized heavily by small- and medium-sized companies in order to introduce novel products to the market. Contract manufacturing allows them to delegate the manufacturing process, freeing up resources and time for R&D efforts.

Key Companies & Market Share Insights

Key companies undertake several strategic initiatives such as partnerships, expansions, new service launches, mergers, and acquisitions to maintain their position in the market. For instance, in January 2023, Aenova Group expanded its capsule filling capacity at the company’s Regensburg site by installing the state-of-the-art IMA Adapta 200 machine. In another instance, in May 2022, Catalent, Inc. announced an investment of USD 175 million to expand its flagship manufacturing facility for large-scale oral dose forms in Winchester, Kentucky. Some of the prominent players in the U.S. oral solid dosage contract manufacturing market include:

  • Catalent, Inc.
  • Lonza
  • AbbVie Inc.
  • Aenova Group
  • Adare Pharma Solutions
  • Boehringer Ingelheim International GmbH
  • Jubilant Pharmova Limited
  • Patheon Pharma Services
  • Recipharm AB
  • Corden Pharma International
  • Siegfried Holding AG

Segments Covered in the Report

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the U.S. Oral Solid Dosage Contract Manufacturing market.

By Product Type 

  • Tablets
  • Capsules
  • Powders
  • Granules
  • Others

By Mechanism 

  • Immediate Release
  • Delayed Release
  • Controlled Release

By End-user 

  • Large Size Companies
  • Medium & Small Size Companies
  • Others

Frequently Asked Questions

The U.S. oral solid dosage contract manufacturing market size was estimated at USD 10.85 billion in 2022 and is expected to hit around USD 19.8 billion by 2032

The key market players offering U.S. oral solid dosage contract manufacturing services include Catalent, Inc., AbbVie Inc., Lonza, Recipharm AB, Thermo Fisher Scientific Inc (Patheon), etc.

Technological advancements pertaining to the development and bulk manufacturing of Oral Solid Dosage (OSD), increasing demand for outsourcing OSD manufacturing among pharmaceutical companies, and growing prevalence of chronic and infectious diseases are few of the major factors supporting the market growth.

The U.S. oral solid dosage contract manufacturing market is expected to grow at a compound annual growth rate of 6.2% from 2023 to 2032

Chapter 1 Methodology And Scope
                  1.1 Market Segmentation And Scope
                      1.1.1 Regional Scope
                      1.1.2 Estimates And Forecast Timeline.
                  1.2 Research Methodology
                  1.3 Information Procurement
                      1.3.1 Purchased Database
                      1.3.2 Nova one advisor Internal Database
                      1.3.3 Secondary Sources
                      1.3.4 Primary Research
                  1.4 Information/data Analysis
                      1.4.1 Information Analysis
                  1.5 Market Formulation & Visualization
                  1.6 Data Validation & Publishing
                  1.7 Market Definitions/scope
                  1.8 Model Details
                      1.8.1 Approach 1: Parent Market Analysis
                      1.8.2 Approach 2: Service/ Commodity Flow Analysis
                      1.8.3 Approach 3: Value-chain-based Sizing & Forecasting
                      1.8.4 Approach 4: Qfd Model Sizing & Forecasting
                  1.9 Market Formulation & Validation
                  1.10 List Of Secondary Sources
                  1.11 List Of Primary Sources
Chapter 2 Executive Summary
                  2.1 Market Snapshot
                  2.2 Segment Snapshot
                  2.3 Segment Snapshot
                  2.4 Competitive Landscape Snapshot
Chapter 3 U.S. Oral Solid Dosage Contract Manufacturing Market: Variables, Trends, & Scope
                  3.1 Market Lineage Outlook
                      3.1.1 Parent Market Outlook
                      3.1.2 Ancillary Market Outlook
                  3.2 U.S. Oral Solid Dosage Contract Manufacturing Dynamics
                  3.3 Market Dynamics
                      3.3.1 Market Driver Impact Analysis
                      3.3.2 Market Restraint Analysis
                  3.4 U.S. Oral Solid Dosage Contract Manufacturing Market: Analysis Tools
                      3.4.1 Porter’s Five Forces Analysis
                      3.4.2 PESTEL Analysis
                  3.5 COVID-19 Impact
                      3.5.1 Activities by Market Players
                      3.5.2 Long-Term Changes in The Pharmaceutical Contract Manufacturing Market
                  3.6 Analysis Pertaining to Oral Solid Dosage Packaging Types in the U.S. by Blisters vs. Bottles (Volume % Share, 2022)
                      3.6.1 Blister Packaging
                      3.6.2 Bottle Packaging
                      3.6.3 Types of Blister Packaging
                          3.6.3.1 Blister Packaging
                  3.7 Regulatory Landscape
                      3.7.1 U.S.
                      3.7.2 Europe
                      3.7.3 Rest Of The World
Chapter 4 U.S. Oral Solid Dosage Contract Manufacturing Market: Product Type Analysis
                  4.1 U.S. Oral Solid Dosage Contract Manufacturing Market by Product Type Segment: Key Takeaways
                  4.2 U.S. Oral Solid Dosage Contract Manufacturing Market: Product Type Movement Analysis
                  4.3 U.S. Oral Solid Dosage Contract Manufacturing Market Estimates & Forecast by Product Type (USD Million)
                      4.3.1 Tablets
                          4.3.1.1 Tablets Contract Manufacturing Market, 2020 - 2032
                      4.3.2 Capsules
                          4.3.2.1 Capsules Contract Manufacturing Market, 2020 - 2032
                      4.3.3 Powders
                          4.3.3.1 Powders Contract Manufacturing Market, 2020 - 2032
                      4.3.4 Granules
                          4.3.4.1 Granules Contract Manufacturing Market, 2020 - 2032
                      4.3.5 Others
                          4.3.5.1 Others Contract Manufacturing Market, 2020 - 2032
Chapter 5 U.S. Oral Solid Dosage Contract Manufacturing Market: Mechanism Analysis
                  5.1 U.S. Oral Solid Dosage Contract Manufacturing Market by Mechanism Segment: Key Takeaways
                  5.2 U.S. Oral Solid Dosage Contract Manufacturing Market: Mechanism Movement Analysis
                  5.3 U.S. Oral Solid Dosage Contract Manufacturing Market Estimates & Forecast by Mechanism (USD Million)
                      5.3.1 Immediate Release
                          5.3.1.1 Immediate Release Contract Manufacturing Market, 2020 - 2032
                      5.3.2 Delayed Release
                          5.3.2.1 Delayed Release Contract Manufacturing Market, 2020 - 2032
                      5.3.3 Controlled Release
                          5.3.3.1 Controlled Release Contract Manufacturing Market, 2020 - 2032
Chapter 6 U.S. Oral Solid Dosage Contract Manufacturing Market: End-user Analysis
                  6.1 U.S. Oral Solid Dosage Contract Manufacturing Market by End-user Segment: Key Takeaways
                  6.2 U.S. Oral Solid Dosage Contract Manufacturing Market: End-user Movement Analysis
                  6.3 U.S. Oral Solid Dosage Contract Manufacturing Market Estimates & Forecast by End User (USD Million)
                      6.3.1 Large-Size Companies
                          6.3.1.1 Large-Size Companies Contract Manufacturing Market, 2020 - 2032
                      6.3.2 Medium & Small-Size Companies
                          6.3.2.1 Medium & Small Size Companies Contract Manufacturing Market, 2020 - 2032
                      6.3.3 Others
                          6.3.3.1 Others Contract Manufacturing Market, 2020 - 2032
Chapter 7 Country Estimates & Trend Analysis, 2020 - 2032
                  7.1 U.S.
                      7.1.1 Key Country Dynamics
                      7.1.2 Competitive Scenario
                          7.1.2.1 U.S. Oral Solid Dosage Contract Manufacturing Market Estimates and Forecasts, 2020 - 2032
Chapter 8 Competitive Landscape
                  8.1 Company Categorization
                  8.2 Service Heat Map Analysis
                  8.3 U.S. Oral Solid Dosage Contract Manufacturing Company Market Share Analysis, 2022
                  8.4 Company Profiles
                      8.4.1 Catalent, Inc.
                          8.4.1.1 Participants’ Overview
                          8.4.1.2 Financial Performance
                          8.4.1.3 Product/Service Benchmarking
                          8.4.1.4 Strategy Initiatives
                      8.4.2 Lonza
                          8.4.2.1 Participants’ Overview
                          8.4.2.2 Financial Performance
                          8.4.2.3 Product/Service Benchmarking
                          8.4.2.4 Strategy Initiatives
                      8.4.3 AbbVie Inc.
                          8.4.3.1 Participants’ Overview
                          8.4.3.2 Financial Performance
                          8.4.3.3 Product/Service Benchmarking
                          8.4.3.4 Strategy Initiatives
                      8.4.4 Aenova Group
                          8.4.4.1 Participants’ Overview
                          8.4.4.2 Financial Performance
                          8.4.4.3 Product/Service Benchmarking
                          8.4.4.4 Strategy Initiatives
                      8.4.5 Adare Pharma Solutions
                      8.4.6 Boehringer Ingelheim International GmbH
                      8.4.7 Jubilant Pharmova Limited
                      8.4.8 Patheon Pharma Services
                      8.4.9 Recipharm AB.
                      8.4.10 Corden Pharma International
                      8.4.11 Siegfried Holding AG

Proceed To Buy

USD 3800
USD 1900
USD 1200

Customization Offered

  • check-img Cross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers